Compare NABL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.6M | 885.7M |
| IPO Year | 2021 | 2020 |
| Metric | NABL | PHAR |
|---|---|---|
| Price | $4.36 | $14.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.31 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 2.4M | 4.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $511,430,000.00 | N/A |
| Revenue This Year | $11.04 | $10.04 |
| Revenue Next Year | $8.53 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $2.92 | $9.54 |
| 52 Week High | $9.04 | $21.34 |
| Indicator | NABL | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 69.20 | 58.71 |
| Support Level | $4.15 | $12.98 |
| Resistance Level | $5.11 | $14.81 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | 0.17 | 0.20 |
| Stochastic Oscillator | 94.72 | 67.94 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.